Advertisement

Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer

  • Hideaki MiyakeEmail author
  • Yuto Matsushita
  • Hiromitsu Watanabe
  • Keita Tamura
  • Daisuke Motoyama
  • Toshiki Ito
  • Takayuki Sugiyama
  • Atsushi Otsuka
Original Article
  • 47 Downloads

Abstract

Background

To compare the prognostic outcomes between first-generation antiandrogen (FGA) and novel androgen-receptor-axis-targeted agent (ARATA) as first-line therapy in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

Methods

This study retrospectively included a total of 103 consecutive nmCRPC patients consisting of 47 (45.6%) and 56 (54.4%) who received FGA (bicalutamide or flutamide) and ARATA (abiraterone acetate or enzalutamide), respectively, as the first-line agent after the failure of primary androgen deprivation therapy (ADT).

Results

There were no significant differences in the major clinicopathological parameters and previous therapeutic histories between the FGA and ARATA groups. During the observation period, 31 (66.0%) and 29 (51.8%) discontinued first-line therapy in the FGA and ARATA groups, respectively, and of these, 27 (87.1%) and 23 (79.3%) in the FGA and ARATA groups, respectively, were subsequently treated with approved agents as second-line therapy. The prostate-specific antigen (PSA) response rate in the FGA group was significantly lower than that in the ARATA group. Although no significant difference in overall survival was noted between the FGA and ARATA groups, there were significant differences in the PSA progression-free survival on first-line therapy and metastasis-free survival between the two groups, favoring the ARATA group compared with FGA group.

Conclusions

Collectively, these findings suggest that among nmCRPC patients who progressed following treatment with the primary ADT, the introduction of ARATA may result in the delay of disease progression compared with FGA.

Keywords

Non-metastatic castration-resistant prostate cancer First-generation antiandrogen Androgen-receptor-axis-targeted agent Prognosis 

Notes

Compliance with ethical standards

Conflict of interest

All authors have declared no conflict of interest.

References

  1. 1.
    Sharifi N, Gulley JL, Dahut WL (2010) An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 17:R305–R315CrossRefGoogle Scholar
  2. 2.
    Fitzpatrick JM, Bellmunt J, Fizazi K et al (2014) Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 50:1617–1627CrossRefGoogle Scholar
  3. 3.
    Rozet F, Roumeguère T, Spahn M et al (2016) Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management. World J Urol 34:1505–1513CrossRefGoogle Scholar
  4. 4.
    Luo J, Beer TM, Graff JN (2016) Treatment of nonmetastatic castration-resistant prostate cancer. Oncology 30:336–344Google Scholar
  5. 5.
    Smith MR, Saad F, Oudard S et al (2013) Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31:3800–3806CrossRefGoogle Scholar
  6. 6.
    Moreira DM, Howard LE, Sourbeer KN et al (2016) Predictors of time to metastasis in castration-resistant prostate cancer. Urology 96:171–176CrossRefGoogle Scholar
  7. 7.
    Smith MR, Saad F, Chowdhury S et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378:1408–1418CrossRefGoogle Scholar
  8. 8.
    Hussain M, Fizazi K, Saad F et al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378:2465–2474CrossRefGoogle Scholar
  9. 9.
    Ryan CJ, Crawford ED, Shore ND et al (2018) The IMAAGEN study: effect of abiraterone acetate and prednisone on prostate specific antigen and radiographic disease progression in patients with nonmetastatic castration resistant prostate cancer. J Urol 200:344–352CrossRefGoogle Scholar
  10. 10.
    Mizokami A, Kadono Y, Kitagawa Y et al (2017) Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. Int J Urol 24:566–572CrossRefGoogle Scholar
  11. 11.
    Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159CrossRefGoogle Scholar
  12. 12.
    Momozono H, Miyake H, Tei H et al (2016) Clinical outcomes of anti-androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial maximum androgen blockade. Mol Clin Oncol 4:839–844CrossRefGoogle Scholar
  13. 13.
    Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152–160CrossRefGoogle Scholar
  14. 14.
    Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433CrossRefGoogle Scholar
  15. 15.
    Penson DF, Armstrong AJ, Concepcion R et al (2016) Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE Trial. J Clin Oncol 34:2098–2106CrossRefGoogle Scholar
  16. 16.
    Beheshti M, Rezaee A, Geinitz H et al (2016) Evaluation of prostate cancer bone metastases with 18F-NaF and 18F-Fluorocholine PET/CT. J Nucl Med 57(Suppl 3):55S–560SCrossRefGoogle Scholar
  17. 17.
    Schwarzenboeck SM, Rauscher I, Bluemel C et al (2017) PSMA Ligands for PET Imaging of Prostate Cancer. J Nucl Med 58:1452–1545CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  • Hideaki Miyake
    • 1
    Email author
  • Yuto Matsushita
    • 1
  • Hiromitsu Watanabe
    • 1
  • Keita Tamura
    • 1
  • Daisuke Motoyama
    • 1
  • Toshiki Ito
    • 1
  • Takayuki Sugiyama
    • 1
  • Atsushi Otsuka
    • 1
  1. 1.Department of UrologyHamamatsu University School of MedicineHamamatsuJapan

Personalised recommendations